ASAP is committed to accelerating the pace of discovery and informing a path to a cure for Parkinson’s disease through collaboration, research-enabling resources, and data sharing. We’ve created this catalog to showcase the research outputs and tools developed by ASAP-funded programs.


Parkinson’s disease and cancer: a systematic re and meta-analysis of over 17 million participants

Published: The authors examined risk association between Parkinson’s disease and cancer using data from 63 publications, totaling in 17 million individuals. With the exception of melanoma, the authors found that the risk association of Parkinson’s disease and cancer was inversely related.


Post mortem human substantial nigra TH staining

This protocol is standardized for postmortem (frozen) SN tissue from pathologically diagnosed PD patients and control individuals for Immunofluorescence staining.


Unilateral intranigral AAV alpha synuclein mouse model

This protocol details methods for the unilateral intranigral AAV alpha-synuclein injection.


Striatal dopamine measurement through HPLC

Protocol for striatal dopamine measurement in mouse brain


DOPA pheomelanin is increased in neuromelanin of Parkinson’s disease substantia nigra and it exacerbates alpha-synuclein neurotoxicity

Preprint: Neuromelanin in the substantia nigra may be a key factor contributing to dopaminergic neuron vulnerability in Parkinson’s disease. Neuromelanin consists of pheomelanin and eumelanin moieties. Here, the authors investigated the relative composition and specific roles of pheomelanin and eumelanin moieties of NM in PD.